274例胰腺癌临床病理特征及影响患者预后的危险因素
Analysis of Clinicopathological Features of 274 Cases of Pancreatic Cancer and Risk Factors Affecting Prognosis
-
摘要: 目的 分析胰腺癌临床病理特征及影响患者预后的危险因素。方法 回顾性分析2012年3月至2017年3月四川大学华西医院274例胰腺癌患者临床资料及随访情况 (随访截止至2018年6月或患者死亡) 。采用Kaplan-Meier法评估患者生存状况, 以Log-rank检验进行单因素分析, 以Cox比例风险回归模型进行多因素分析, 筛选出影响胰腺癌患者预后的危险因素。结果 至随访终点, 274例患者中, 242例死亡, 32例存活, 中位生存时间为5.7个月, 1 a、2 a、3 a生存率分别为24.6%、10.7%、4.6%。单因素分析显示, 肿瘤部位、肿瘤大小、c TNM分期、有无肝转移、有无淋巴结转移、治疗方式、血清CEA水平、血清CA199水平、血清CA242水平、NLR与胰腺癌患者预后有关 (P <0.05) , 而性别、年龄、体质量指数、有无糖尿病史、有无吸烟史、血清ALB水平与胰腺癌患者预后无关 (P> 0.05) 。Cox多因素分析显示, 肿瘤大小>2 cm、c TNM分期为III~IV期、淋巴结转移、血清CA199>37 U/m L、血清CA242>20 U/m L、NLR> 4均是胰腺癌患者预后的独立危险因素 (P <0.05) , 而手术治疗是胰腺癌患者预后的有益因素 (P <0.05) 。结论 肿瘤大小、c TNM分期、淋巴结转移、血清CA199及CA242水平、NLR及治疗方式与胰腺癌患者预后密切相关。Abstract: Objective To analyze the clinicopathological features of pancreatic cancer and the risk factors affecting the prognosis. Methods The clinical data and follow-up condition of 274 patients with pancreatic cancer in our hospital from March 2012 to March 2017 were retrospectively analyzed (the follow-up was until June 2018 or the patient died) . Kaplan-Meier method was used to evaluate the survival of patients. Log-rank test was used for univariate analysis. Cox proportional hazard regression model was used for multivariate analysis to screen out the risk factors affecting the prognosis of patients with pancreatic cancer. Results By the end of follow-up, 242 cases died and 32 cases survived among 274 cases of patients, and the median survival time was 5.7 months, and the1-year, 2-year and 3-year survival rates were 24.6%, 10.7% and 4.6% respectively. Univariate analysis showed that tumor location, tumor size, c TNM stage, presence or absence of liver metastasis or lymph node metastasis, treatment methods, serum CEA level, serum CA199 level, serum CA242 level and NLR were associated with prognosis in patients with pancreatic cancer (P < 0.05) , but gender, age, BMI, presence or absence of diabetes history or smoking history, serum ALB level were not associated with prognosis in patients with pancreatic cancer (P > 0.05) . Cox multivariate analysis showed that tumor size > 2 cm, c TNM stage III-IV, lymph node metastasis, serum CA199 > 37 U/m L, serum CA242 > 20 U/m Ll and NLR > 4 were independent risk factors for prognosis of patients with pancreatic cancer (P<0.05) , and surgical treatment was a beneficial factor for prognosis of patients with pancreatic cancer (P < 0.05) . Conclusions Tumor size, c TNM stage, lymph node metastasis, serum CA199 and CA242 levels, NLR and treatment methods are closely related to the prognosis of patients with pancreatic cancer.
-
Key words:
- Pancreatic cancer /
- Clinicopathological features /
- Prognosis /
- Risk factors
-
[1]杨尹默.胰腺癌外科治疗的现状、存在问题与展望[J].中国普通外科杂志, 2016, 25 (9) :1231-1235. [2]吴永杰, 刘海亮, 胡明根, 等.术前中性粒细胞与淋巴细胞比值对胰腺癌预后的判断价值[J].中华医学杂志, 2015, 95 (28) :2291-2293. [3]雷学芬, 林劼, 江利锋, 等.立体定向放射治疗中晚期胰腺癌临床疗效观察[J].昆明医科大学学报, 2015, 36 (8) :103-106. [4]刘肇修, 肖明兵, 江枫, 等.胰腺癌患者预后的影响因素分析及其对生存结局的预测价值[J].山东医药, 2016, 56 (40) :53-55. [5]秦仁义.指导手术方式选择的胰腺癌分型及其与TNM分期相关性的探讨[J].中华外科杂志, 2015, 53 (7) :488-491. [6] [6]KURIHARA T, KOGO M, ISHII M, et al.Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1[J].Hepato-gastroenterology, 2015, 62 (138) :478-484. [7] [7]IPPEI M, YOSHIAKI M, MAKOTO S, et al.Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection:A multi-center retrospective study[J].Pancreatology, 2015, 15 (6) :674-680. [8] [8]AHMAD J, GRIMES N, FARID S, et al.Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma:a systematic review[J].Hepatobiliary&Pancreatic Diseases International, 2014, 13 (5) :474-481. [9] [9]YAMAMOTO T, YAGI S, KINOSHITA H, et al.Long-term survival after resection of pancreatic cancer:A single-center retrospective analysis[J].World Journal of Gastroenterology, 2015, 21 (1) :262-268. [10]李翀, 唐纯娜, Chong LI, 等.转录因子Sp3表达与胰腺癌临床病理特征及预后的关系[J].中国现代医学杂志, 2015, 25 (18) :12-15. [11]王卓, 刘德军, 霍砚淼, 等.淋巴结转移对胰腺癌患者生存期的影响[J].中华肝胆外科杂志, 2016, 22 (10) :672-676. [12]马学柱.血清CA199CA125CA242癌胚抗原表达水平与胰腺癌的早期诊断和预后转归的关联性研究[J].山西医药杂志, 2016, 45 (13) :1543-1545. [13]杨柳, 闫欢, 石燕, 等.晚期胰腺癌患者血清CA125, CA199水平与肝转移的关系[J].中国实验诊断学, 2017, 21 (5) :770-773. [14]彭维忠, 杨浩洁, 张克兰, 等.外周血NLR或PLR与结直肠癌预后的相关性研究进展[J].中国免疫学杂志, 2017, 33 (12) :1902-1906. [15]张文琪, 郝权.术前外周血NLR对上皮性卵巢癌患者预后的影响[J].中国肿瘤临床, 2014, 41 (10) :634-638. [16] [16]KANG M H, GO S I, SONG H N, et al.The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer[J].British Journal of Cancer, 2014, 111 (3) :452-460. [17] [17]BHATTI I, PEACOCK O, LLOYD G, et al.Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma:neutrophil-lymphocyte versus platelet-lymphocyte ratio[J].American Journal of Surgery, 2010, 200 (2) :197-203. [18] [18]XUE P, KANAI M, MORI Y, et al.Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J].Cancer Medicine, 2014, 3 (2) :406-415. [19]杨科, 单祖建, 周琼华, 等.可溶性细胞因子受体及基质金属蛋白酶与胰腺癌的关系[J].昆明医科大学学报, 2017, 38 (1) :99-102. [20]孙岩娜, 张华, 张瑞丽, 等.新疆维吾尔族与汉族入院治疗胰腺癌患者353例预后因素分析[J].中华肿瘤防治杂志, 2013, 20 (18) :1436-1440.
点击查看大图
计量
- 文章访问数: 3793
- HTML全文浏览量: 1497
- PDF下载量: 147
- 被引次数: 0